TCT-291 Comparison of Thromboresistance Between Everolimus-Eluting Fluoropolymer Stent and Currently Available Drug-Eluting Stent in an Ex Vivo Swine Shunt Model Under Only Single Antiplatelet Therapy

Recent clinical studies suggest that 1-month dual antiplatelet therapy is feasible for patients receiving Xience everolimus-eluting stents, but whether this applies to other current drug-eluting stents (DES) remains uncertain. Under low-dose heparin treatment, ex vivo porcine arteriovenous shunt